Next generation antihistamines: therapeutic rationale, accomplishments and advances

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Expert Opinion on Investigational Drugs

• Publication date

  2002-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/13543784.11.6.807PMID 12036424
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Thymus and activation-regulated chemokine in atopic dermatitis: Serum thymus and activation-regulated chemokine level is closely related with disease activity.

  2001cited by this paper
• Desloratadine activity in concurrent seasonal allergic rhinitis and asthma

  2001cited by this paper
• Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine

  2001cited by this paper
• The effect of rifampin administration on the disposition of fexofenadine

  2001cited by this paper
• Desloratadine: A new, nonsedating, oral antihistamine.

  2001cited by this paper
• Suppression of the early and late cutaneous allergic responses using fexofenadine and montelukast.

  2001cited by this paper
• Effect of cetirizine, levocetirizine, and dextrocetirizine on histamine‐induced nasal response in healthy adult volunteers

  2001influential reference
• Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season.

  2001cited by this paper
• Once‐daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double‐blind, placebo‐controlled study

  2001cited by this paper
• A randomized, double‐blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine‐induced cutaneous responses in healthy adult volunteers

  2001cited by this paper
• No drug interaction between fluoxetine and desloratadine, a new nonsedating once-daily antihistamine

  2001cited by this paper
• Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease.

  2001cited by this paper
• Twenty-four hours of activity of cetirizine and fexofenadine in the skin.

  2001cited by this paper
• Pharmacokinetic and safety profile of desloratadine and fexofenadine when coadministered with azithromycin: a randomized, placebo-controlled, parallel-group study.

  2001influential reference
• The pharmacologic profile of desloratadine: a review

  2001cited by this paper
• Skin concentrations of H1-receptor antagonists.

  2001cited by this paper
• Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria.

  2000cited by this paper
• Effects of Fexofenadine, Diphenhydramine, and Alcohol on Driving Performance

  2000cited by this paper
• Loratadine versus cetirizine: assessment of somnolence and motivation during the workday.

  2000cited by this paper
• Structural basis of HERG potassium channel function

  2000cited by this paper
• Effects of fexofenadine, diphenhydramine, and alcohol on driving performance. A randomized, placebo-controlled trial in the Iowa driving simulator.

  2000cited by this paper
• Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions.

  2000cited by this paper
• Preclinical Pharmacology of Desloratadine, a Selective and Nonsedating Histamine H1 Receptor Antagonist

  2000influential reference
• Preclinical Pharmacology of Desloratadine, a Selective and Nonsedating Histamine H1 Receptor Antagonist2nd Communication: Lack of central nervous system and cardiovascular effects

  2000cited by this paper
• Hepatic Disposition of Fexofenadine: Influence of the Transport Inhibitors Erythromycin and Dibromosulphothalein

  2000cited by this paper
• Comparison of the efficacy, safety and quality of life provided by fexofenadine hydrochloride 120 mg, loratadine 10 mg and placebo administered once daily for the treatment of seasonal allergic rhinitis

  2000cited by this paper
• Evaluation of the pharmacokinetics and electrocardiographic pharmacodynamics of loratadine with concomitant administration of ketoconazole or cimetidine.

  2000cited by this paper
• QT lengthening and life-threatening arrhythmias associated with fexofenadine.

  2000cited by this paper
• QT lengthening and life-threatening arrhythmias associated with fexofenadine.

  1999cited by this paper
• A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function.

  1999cited by this paper
• A double‐blind, single‐dose, crossover comparison of cetirizine, ebastine, epinastine, fexofenadine, terfenadine, and loratadine versus placebo: suppression of histamine‐induced wheal and flare response for 24 h in healthy male subjects

  1999cited by this paper
• Cardiovascular safety of fexofenadine HCl

  1999cited by this paper
• QT lengthening and arrhythmias associated with fexofenadine.

  1999cited by this paper
• Clinical Pharmacology of New Histamine H1 Receptor Antagonists

  1999influential reference
• Inhibition of histamine or allergen-induced wheals by a single dose of acrivastine, fexofenadine or cetirizine.

  1999cited by this paper
• Comparison of the effects of terfenadine with fexofenadine on nasal provocation tests with allergen.

  1999cited by this paper
• Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle.

  1999cited by this paper
• Block of HERG Potassium Channels by the Antihistamine Astemizole and its Metabolites Desmethylastemizole and Norastemizole

  1999cited by this paper
• Safety and efficacy of once-daily fexofenadine HCl in the treatment of autumn seasonal allergic rhinitis.

  1999cited by this paper
• Cardiovascular safety of fexofenadine HCl.

  1999cited by this paper
• The efficacy and safety of fexofenadine HCl and pseudoephedrine, alone and in combination, in seasonal allergic rhinitis.

  1999cited by this paper
• Once-daily fexofenadine HCl improves quality of life and reduces work and activity impairment in patients with seasonal allergic rhinitis.

  1999cited by this paper
• Double-blind, placebo-controlled study comparing the efficacy and safety of fexofenadine hydrochloride (120 and 180 mg once daily) and cetirizine in seasonal allergic rhinitis.

  1999cited by this paper
• Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance.

  1998cited by this paper
• Effect of fexofenadine on eosinophil-induced changes in epithelial permeability and cytokine release from nasal epithelial cells of patients with seasonal allergic rhinitis.

  1998cited by this paper
• Pharmacokinetics, pharmacodynamics, and tolerance of single‐ and multiple‐dose fexofenadine hydrochloride in healthy male volunteers

  1998cited by this paper
• Terfenadine and fexofenadine reduce in vitro ICAM-1 expression on human continuous cell lines.

  1998cited by this paper
• Therapeutic advantages of third generation antihistamines.

  1998influential reference
• Effectiveness and safety of fexofenadine, a new nonsedating H1-receptor antagonist, in the treatment of fall allergies.

  1998cited by this paper
• Onset of action, efficacy, and safety of a single dose of fexofenadine hydrochloride for ragweed allergy using an environmental exposure unit.

  1997cited by this paper
• Effect of food on the bioavailability of fexofenadine hydrochloride (MDL 16455A).

  1997cited by this paper
• Peripheral H1-blockade effect of fexofenadine.

  1997cited by this paper
• Loratadine and desethoxylcarbonyl‐loratadine inhibit the immunological release of mediators from human FcɛRI+cells

  1997cited by this paper
• Loratadine and desethoxylcarbonyl-loratadine inhibit the immunological release of mediators from human Fc epsilon RI+ cells.

  1997cited by this paper
• Efficacy and safety of fexofenadine hydrochloride for treatment of seasonal allergic rhinitis.

  1997cited by this paper
• Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram

  1996cited by this paper
• Comparative analysis of the cardiotoxicity proclivities of second generation antihistamines in an experimental model predictive of adverse clinical ECG effects.

  1996cited by this paper
• HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine.

  1996cited by this paper
• Cardiac actions of antihistamines.

  1996influential reference
• Special Considerations in the Treatment of Seasonal Allergic Rhinitis in Adolescents: The Role of Antihistamine Therapy

  1996cited by this paper
• Comparison of the central nervous system effects produce by six H1‐receptor antagonists

  1996cited by this paper
• Antihistamine activity, central nervous system and cardiovascular profiles of histamine H1 antagonists: comparative studies with loratadine, terfenadine and sedating antihistamines in guinea‐pigs

  1995cited by this paper
• Pharmacological modulation of IL‐6 and IL‐8 secretion by the H1‐antagonist decarboethoxy‐loratadine and dexamethasone by human mast and basophilic cell lines

  1995cited by this paper
• Loratadine administered concomitantly with erythromycin: Pharmacokinetic and electrocardiographic evaluations

  1995cited by this paper
• Cardiac electrophysiological actions of the histamine H1-receptor antagonists astemizole and terfenadine compared with chlorpheniramine and pyrilamine.

  1995cited by this paper
• Inhibitory activity of loratadine and descarboethoxyloratadine on expression of ICAM‐1 and HLA‐DR by nasal epithelial cells

  1995cited by this paper
• The pharmacology and use of H1-receptor-antagonist drugs.

  1994cited by this paper
• In vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3).

  1994cited by this paper
• The electrocardiographic effects of cetirizine in normal subjects

  1994cited by this paper
• Inhibition of IgE- and non-IgE-mediated histamine release from human basophil leukocytes in vitro by a histamine H1-antagonist, desethoxycarbonyl-loratadine.

  1994cited by this paper
• Mechanism of the cardiotoxic actions of terfenadine.

  1993cited by this paper
• Effects of terfenadine and its metabolites on a delayed rectifier K+ channel cloned from human heart.

  1993cited by this paper
• Antiallergic effects of major metabolites of astemizole in rats and guinea pigs.

  1991cited by this paper
• Astemizole: A Long-Acting, Nonsedating Antihistamine

  1987cited by this paper
• Effect of the nonsedative H1-receptor antagonist astemizole in perennial allergic and nonallergic rhinitis.

  1985cited by this paper
• Astemizole: a new long‐acting antihistamine in the treatment of seasonal allergic rhinitis

  1983cited by this paper
• Pharmacokinetics and biotransformation studies of terfenadine in man.

  1982cited by this paper

• Pathogenesis of allergic diseases and implications for therapeutic interventions

  2023cites this paper
• Mechanism and clinical evidence of immunotherapy in allergic rhinitis

  2023cites this paper
• Crosstalk between AdipoR1/AdipoR2 and Nrf2/HO‐1 signal pathways activated by β‐caryophyllene suppressed the compound 48/80 induced pseudo‐allergic reactions

  2021cites this paper
• Anti-allergic actions of a Chinese patent medicine, huoxiangzhengqi oral liquid, in RBL-2H3 cells and in mice

  2021cites this paper
• Discovery of Potent Antiallergic Agents Based on an o-Aminopyridinyl Alkynyl Scaffold.

  2021cites this paper
• Investigation of the molecular mechanism underlying the inhibitory activities of ethanol extract of Bombyx mori pupa-incubated Cordyceps militaris fruiting bodies toward allergic rhinitis.

  2021cites this paper
• Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation.

  2020cites this paper
• Polyethylenimine-Multi-Walled Carbon Nanotubes/Glassy Carbon Electrode as an Efficient Sensing Platform for Promethazine

  2020cites this paper
• Hydroxychloroquine and “off-label” utilization in the treatment of oral conditions

  2020cites this paper
• Inhibitory Effects of Eriodictyol-7-O-β-d-glucuronide and 5,7-Dihydroxy-4-chromene Isolated from Chrysanthemum zawadskii var. latilobum in FcεRI-Mediated Human Basophilic KU812F Cell Activation

  2020cites this paper
• Neohesperidin suppresses IgE‐mediated anaphylactic reactions and mast cell activation via Lyn‐PLC‐Ca2+ pathway

  2019cites this paper
• Berberine suppresses mast cell-mediated allergic responses via regulating FcɛRI-mediated and MAPK signaling.

  2019cites this paper
• Magnolin inhibits IgE/Ag-induced allergy in vivo and in vitro.

  2019cites this paper
• Development of sodium hyaluronate-based formulations loaded with nanosuspension for nasal delivery of loratadine

  2019cites this paper
• GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society)

  2018cites this paper
• LAT is essential for the mast cell stabilising effect of tHGA in IgE‐mediated mast cell activation

  2017cites this paper
• Inhibition of Mast Cell-Mediated Allergic Responses by Arctii Fructus Extracts and Its Main Compound Arctigenin.

  2017cites this paper
• Anti‐allergic activity of 2,4,6‐trihydroxy‐3‐geranylacetophenone (tHGA) via attenuation of IgE‐mediated mast cell activation and inhibition of passive systemic anaphylaxis

  2017cites this paper
• Antiallergic effect of fisetin on IgE-mediated mast cell activation in vitro and on passive cutaneous anaphylaxis (PCA).

  2017cites this paper
• Suppression of the Eag1 potassium channel sensitizes glioblastoma cells to injury caused by temozolomide

  2016cites this paper
• Targeting mast cells: Uncovering prolific therapeutic role in myriad diseases.

  2016cites this paper
• Chapter 16 – Antihistamine Drugs

  2016cites this paper
• GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1–2 September 2014

  2015cites this paper
• Development and evaluation of in situ nasal gel formulations of loratadine

  2015cites this paper
• Aceriphyllum rossii extract and its active compounds, quercetin and kaempferol inhibit IgE-mediated mast cell activation and passive cutaneous anaphylaxis.

  2014cites this paper
• The inhibitory activity of atractylenolide Ш, a sesquiterpenoid, on IgE-mediated mast cell activation and passive cutaneous anaphylaxis (PCA).

  2013cites this paper
• Anti-inflammatory and anti-allergic activities of sea cucumber (Stichopus japonicus) extract

  2013cites this paper
• Antiallergic activity of novel isoflavone methyl-glycosides from Cordyceps militaris grown on germinated soybeans in antigen-stimulated mast cells.

  2012cites this paper
• Phototherapy for the Treatment of Allergic Rhinitis

  2012cites this paper
• 11 Phototherapy for the Treatment of Allergic Rhinitis

  2012cites this paper
• The ethyl acetate extract of Cordyceps militaris inhibits IgE-mediated allergic responses in mast cells and passive cutaneous anaphylaxis reaction in mice.

  2011cites this paper
• Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development.

  2009cites this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cites this paper
• Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development.

  2009cites this paper
• Epinastine: topical ophthalmic second generation antihistamine without significant systemic side effects

  2009cites this paper
• Enantiomeric purity control of levocetirizine in pharmaceuticals using anionic cyclodextrin mediated capillary electrophoresis separation and fiber-based diode array detection.

  2009cites this paper
• Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

  2009cites this paper
• Types of Hypersomnias

  2008cites this paper
• Discovery of the first nonpeptidic, small-molecule, highly selective somatostatin receptor subtype 5 antagonists: a chemogenomics approach.

  2007cites this paper
• Allergic rhinitis and its pharmacology.

  2007cites this paper
• Roles of histamine and its receptors in allergic and inflammatory bowel diseases.

  2005cites this paper
• Norpiperidine imidazoazepines as a new class of potent, selective, and nonsedative H1 antihistamines.

  2005cites this paper
• Role of histamine and platelet-activating factor in allergic rhinitis

  2004cites this paper
• New targets for allergic rhinitis — a disease of civilization

  2003cites this paper
• Determinants of histamine recognition: implications for the design of antihistamines.

  2003cites this paper